NASDAQ:ATHX Athersys (ATHX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ATHX Stock Alerts $0.0047 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.0045▼$0.006050-Day Range$0.0022▼$0.015052-Week Range$0.01▼$1.99Volume396,725 shsAverage Volume1.77 million shsMarket Capitalization$290,079.30P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Athersys alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Athersys Stock (NASDAQ:ATHX)Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Read More ATHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHX Stock News HeadlinesApril 20, 2024 | americanbankingnews.comAthersys (NASDAQ:ATHX) Research Coverage Started at StockNews.comApril 8, 2024 | bizjournals.comBankruptcy of once-promising Athersys winding down with assets saleApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. February 26, 2024 | investing.comToughbuilt Industries Inc (TBLT)February 17, 2024 | morningstar.comAthersys Inc ATHXQJanuary 8, 2024 | marketwatch.comAthersys to Sell Most Assets to HealiosNovember 16, 2023 | finance.yahoo.comAthersys Reports Third Quarter 2023 Financial Results and Business HighlightsOctober 23, 2023 | bizjournals.comAthersys shares migrate to Pink marketplace for broker-to-broker tradingApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. October 20, 2023 | bizjournals.comAthersys shares delisted by Nasdaq Stock MarketOctober 16, 2023 | finance.yahoo.comAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesOctober 10, 2023 | msn.comAthersys crashes after bankruptcy warningOctober 10, 2023 | finance.yahoo.comAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosOctober 3, 2023 | businesswire.comAthersys Licenses its Animal Health Assets to Ardent Animal HealthOctober 2, 2023 | finance.yahoo.comAthersys Director Jane Wasman Appointed Board ChairSeptember 26, 2023 | finance.yahoo.comAthersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst BlogSeptember 6, 2023 | finance.yahoo.comGrant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney TransplantationAugust 25, 2023 | finance.yahoo.comIs Athersys Inc (ATHX) Significantly Overvalued?August 18, 2023 | marketwatch.comAthersys Shares Tumble 26% After Pricing Public OfferingAugust 18, 2023 | investorplace.comWhy Is Athersys (ATHX) Stock Down 36% Today?August 18, 2023 | seekingalpha.comAthersys shares slide on pricing $3.5 million stock offeringAugust 18, 2023 | finance.yahoo.comAthersys, Inc. Announces Pricing of $3.5 Million Public OfferingAugust 16, 2023 | finance.yahoo.comAthersys Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 11, 2023 | finance.yahoo.comAthersys Appoints Neema Mayhugh, PhD to its Board of DirectorsAugust 11, 2023 | bizjournals.comAthersys executives foresee catalysts that could ease its financial journeyJuly 31, 2023 | businesswire.comAthersys to Host Business Update Conference Call on August 9thJuly 30, 2023 | fool.comAthersys (NASDAQ: ATHX)See More Headlines Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATHX CUSIPN/A CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees24Year Founded1995Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,530,000.00 Net MarginsN/A Pretax Margin-46,304.93% Return on EquityN/A Return on Assets-223.03% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$146,000.00 Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value($1.33) per share Price / Book0.00Miscellaneous Outstanding Shares61,719,000Free Float61,700,000Market Cap$290,079.30 OptionableNo Data Beta-0.90 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel A. Camardo M.B.A. (Age 54)CEO, Secretary & Director Comp: $796.81kMs. Z. Kasey Rosado (Age 49)Interim Chief Financial Officer Comp: $1.51MMs. Maia A. Hansen M.B.A. (Age 54)M.S., Chief Operating Officer Comp: $962.57kSenthil Ranganathan Ph.D.Vice President of Technical OperationsMr. David Russ M.B.A.Vice President of Supply Chain, Finance & AdministrationDr. Manal Morsy M.B.A.M.D., PH.D., Executive VP & Head of Global Regulatory AffairsDr. Robert Mays Ph.D.Executive VP, Head of Regenerative Medicine & Neuroscience ProgramsMr. Rakesh Ramachandran MSHead of Information Technology & Communications and VPDr. Sarah Busch Ph.D.VP of Regenerative Medicine & Head of Business DevelopmentMs. Ellen GurleyManager of Corporate Communications and Investor RelationsMore ExecutivesKey CompetitorsAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEObsEvaNASDAQ:OBSVCalithera BiosciencesNASDAQ:CALAAllarity TherapeuticsNASDAQ:ALLRView All Competitors ATHX Stock Analysis - Frequently Asked Questions How have ATHX shares performed in 2024? Athersys' stock was trading at $0.02 at the start of the year. Since then, ATHX shares have decreased by 76.5% and is now trading at $0.0047. View the best growth stocks for 2024 here. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.25. The biopharmaceutical company earned $4.79 million during the quarter. During the same quarter in the previous year, the business posted ($2.75) EPS. When did Athersys' stock split? Athersys shares reverse split on the morning of Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is William (B.J.) Lehmann's approval rating as Athersys' CEO? 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). How do I buy shares of Athersys? Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATHX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
